Synucure Therapeutics conducts biotechnology research focused on developing treatments for brain degenerative disorders, specifically Parkinson's disease. The company is advancing Cysteamine as a potential Disease Modifying Therapy (DMT) based on preclinical findings showing its ability to prevent or reverse PD-related features. Furthermore, they are developing patented blood biomarkers intended to offer clinicians a precise, non-invasive diagnostic tool for Parkinson's disease detection.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson's disease is a progressive neurodegenerative disorder with limited treatment options that only address symptoms, failing to halt or reverse disease progression. Existing diagnostic methods lack the precision and speed needed for early detection and stratification of patients, hindering timely intervention and personalized treatment strategies.
Solution
Synucure Therapeutics is developing a disease-modifying therapy (DMT), SYN-001, a novel formulation of cysteamine, with the potential to halt or reverse the progression of Parkinson's disease. Pre-clinical studies have demonstrated neuroprotective and neurorestorative effects of cysteamine in animal and human cell models relevant to Parkinson's disease. In addition, Synucure is developing a blood-based biomarker diagnostic tool to enable faster and more accurate diagnosis and stratification of Parkinson's disease patients. This diagnostic tool aims to provide clinicians with a more precise method for early detection and monitoring of the disease.
Target Audience
The primary target audience includes clinicians, patients, and the pharmaceutical industry involved in the diagnosis, treatment, and research of Parkinson's disease.
Features
- SYN-001: A novel formulation of cysteamine designed as a disease-modifying therapy for Parkinson's disease.
- Cysteamine: Demonstrates neuroprotective and neurorestorative effects in pre-clinical models.
- Blood-based Biomarkers: Patented biomarkers for rapid and accurate diagnosis of Parkinson’s disease.
- Clinical Programs: Focused on Disease Modifying Therapy (DMT) and biomarker analysis for Parkinson's disease.